RxDoctor Payments Data

Brett Neustater, MD

Gastroenterology · North Miami Beach, FLNPI 1245212000

Payments from drug & device makers

$8,837in general payments, 2019–2025

Across 395 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$845
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$636
  • Bristol Myers Squibb$472
  • Sanofi$449
  • Pfizer$391
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$160%
  • Food & beverage$8,60897%
  • Education$2132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,837 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$100,529
Medicare patients
316
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$463,650
ZeposiaOzanimod Hydrochloride12$104,545
RinvoqUpadacitinib14$104,448
LinzessLinaclotide67$85,815
XifaxanRifaximin16$42,471
ClenpiqSod Picosulf/Mag Ox/Citric Ac170$28,971
TrulancePlecanatide16$16,521
SutabSod Sulf/Pot Chloride/Mag Sulf57$9,342
Tenofovir Disoproxil Fumarate20$8,369
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,750
Mesalamine19$6,525
Balsalazide Disodium14$2,600
Esomeprazole Magnesium50$2,544
Pantoprazole Sodium154$1,712
Omeprazole97$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$845$463,65017 claims
AbbVieRinvoq, Linzess$2,921$190,26381 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$636$58,99232 claims
Ferring Pharmaceuticals Inc.Clenpiq$237$28,971170 claims
Braintree Laboratories, Inc.Sutab$64$9,34257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →